At Sarepta Therapeutics, we’ve seen it all. Here are the questions I believe we should be asking to move forward in Duchenne ...
After entering the CAR T space in February, Eli Lilly is “jumping into in vivo CAR-T with both feet” with the acquisition of ...
While Merck’s PD-1/VEGF asset appears to match the performance of Summit Therapeutics’ ivonescimab, the pharma’s Phase 1/2 ...
In nuclear medicine, innovation alone isn’t enough. What matters is whether it can be delivered on time, every time, because ...
Novo Nordisk’s etavopivat elicited a 27% drop in vaso-occlusive crises and 48.7% hemoglobin response after 24 weeks, creating ...
An investigational cocktail was tied to a 0% overall response rate in patients with gastroesophageal cancer, but developers ...
Doubling survival in pancreatic cancer, a long-fought rare disease approval, a massive IPO and ambitious biotech ...
Viatris, which Pfizer created in 2020, voluntarily withdrew extended-release products made at a plant in Ireland after an ...
A new executive order could usher in psychedelics as the “key next wave” of mental health therapies, according to analysts at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results